Analyzing...
Loading company...
KMC Speciality Hospitals (India) Ltd. engages in the business of rendering medical and healthcare services. The company is headquartered in Trichy, Tamil Nadu and currently employs 814 full-time employees. The company provides various services through its centers, such as heart and lung transplant, cardiac science, neurology and neuroscience, pulmonology, general medicine, diabetology, orthopedics, spine surgery, gastroenterology, liver disease, transplantation and hepatobiliary surgery, center for advance diagnostic and interventional radiology, nephrology and urology science, vascular surgery, oncology, pediatrics and neonatology, and infectious diseases. Its specialties include Anesthesia, critical care, dental maxillofacial, dermatology, ophthalmology, endocrinology, ENT head and neck surgery, general surgery, laboratory services, obstetrics and gynecology, and rheumatology. The company also provides emergency surgery, acute airway and parenteral access management, trauma, poisoning and burns management, and management of high risk cases of surgery.
No significant concerns identified
Nothing flagged for monitoring
“Operates in Healthcare — Hospitals & Diagnostics.”
₹306 Cr revenue.
COGS 14.7%, employees 21.5%.
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 22.2%▲ | 9.0% |
| ROCE | 24.6%▲ | 10.4% |
| Net Margin | 15.0%▲ | 8.5% |
| EBITDA Margin | 29.9%▲ | 20.6% |
| Debt To Equity | 0.34x▲ | 0.16x |
Revenue segment breakdown not available.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹306 Cr +32.0% | ₹232 Cr +30.7% | ₹177 Cr +13.8% | ₹156 Cr +14.5% | ₹136 Cr +32.6% | ₹103 Cr +6.7% | ₹96 Cr +16.9% | ₹82 Cr |
| Other Income | ₹5 Cr +64.5% | ₹3 Cr -13.3% | ₹4 Cr +13.8% | ₹3 Cr +45.7% | ₹2 Cr +11.4% | ₹2 Cr +35.9% | ₹1 Cr -13.8% | ₹2 Cr |
| Total Income | ₹311 Cr +32.5% | ₹235 Cr +29.8% | ₹181 Cr +13.8% | ₹159 Cr +15.0% | ₹138 Cr +32.2% | ₹105 Cr +7.1% | ₹98 Cr +16.3% | ₹84 Cr |
| COGS | ₹45 Cr +33.7% | ₹34 Cr +37.9% | ₹24 Cr +6.3% | ₹23 Cr +11.7% | ₹21 Cr +25.9% | ₹16 Cr +18.3% | ₹14 Cr +15.5% | ₹12 Cr |
| ₹248 Cr +22.0% | ₹203 Cr +44.9% | ₹140 Cr +14.1% | ₹123 Cr +15.8% | ₹106 Cr +22.7% | ₹87 Cr +6.9% | ₹81 Cr +13.0% | ₹72 Cr | |
| Profit Before Tax | ₹63 Cr +99.4% | ₹32 Cr -22.1% | ₹41 Cr +12.7% | ₹36 Cr +12.1% | ₹32 Cr +77.9% | ₹18 Cr +8.1% | ₹17 Cr +35.4% | ₹12 Cr |
| ₹16 Cr +60.1% | ₹10 Cr -0.0% | ₹10 Cr +9.4% | ₹9 Cr +11.1% | ₹8 Cr +59.0% | ₹5 Cr +6.3% | ₹5 Cr +33.1% | ₹4 Cr | |
| Net Profit | ₹47 Cr +118.1% | ₹21 Cr -29.5% | ₹30 Cr +13.8% | ₹27 Cr +12.5% | ₹24 Cr +85.7% | ₹13 Cr +8.8% | ₹12 Cr +36.4% | ₹9 Cr |
| Other Comprehensive Income | (₹0.64 Cr) +5.8% | (₹0.68 Cr) -124.0% | (₹0.30 Cr) ↓ Decline | ₹0.01 Cr ↑ Recovery | (₹0.25 Cr) -125.3% | (₹0.11 Cr) +29.8% | (₹0.16 Cr) ↓ Decline | ₹0.06 Cr |
| EPS | ₹2.87 | ₹1.31 | ₹1.86 | ₹1.64 | ₹1.45 | ₹0.78 | ₹0.72 | ₹0.53 |
| Diluted Shares | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹16 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
No earnings call transcripts available.
Please find enclosed a copy of the certificate dated July 3, 2026 received from our RTA for the quarter ended June 30, 2026
Investor Presentation for the quarter and year ended 31st March, 2026
Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015 - Purchase of vacant land by the Company
Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015 - Appointment of Internal Auditor for FY 2026-27
Please find enclosed the Standalone Audited Financial Results for the FY 2025-26
Please find enclosed the Standalone Audited Financial results for the Quarter and Year ended 31st March, 2026 along with the Auditors Report as approved by the Board of Directors at their .... Please ...
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</...
Investor Presentation for the quarter and nine months ended December 31, 2025
Intimation under Regulation 30 of SEBI (LODR) Regulations 2015 - Giving Corporate Guarantee/Security.
Please find the enclosed the standalone Unaudited financial results for the Quarter and Nine months ended 31st December, 2025 along with the Limited Review Report of the Statutory Auditors .... Please...
Please find enclosed the Standalone Unaudited Financial results for the Quarter and Nine months ended 31st December, 2025 along with the Limited Review Report of the Statutory Auditors .... Please fin...
Please find enclosed a copy of the certificate dated January 6, 2026 received from our RTA for the quarter ended December 31, 2025.
Newspaper publication regarding special window for re-lodgement of transfer request of physical shares of the Company
Investor presentation for the quarter and half year ended 30th September, 2025.
Please find enclosed the Standalone Unaudited Financial Results for the quarter and half year ended 30th September, 2025 along with the Limited Review report of the Statutory Auditors as .... Please f...
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
No dividend history available for this company.